TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

MYLUNG CONSORTIUM

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: US

Quick snapshot

MYLUNG CONSORTIUM

ST13

US500000090508673

Class

9, 35, 42, 44

Filing

90508673

Registration

6777452

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

26

Latest update

07/05/2022

Classification

Registered

Trademark type

Word

Nice classes

9, 35, 42, 44

Filing date

02/03/2021

Registration date

07/05/2022

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

07/05/2022

Last transaction

07/05/2022

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

01/26/2021

First use in commerce

01/26/2021

Drawing code

4

Owner type

03

Owner location

Irving, TX, US

Examiner

QUEEN, ESTHER FELICIA

Law office

M20

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

M. C. (pessoa física)

Representatives

Auma N. Reggy MCKESSON CORPORATION

Technical classification

Nice Classes

Class 9Class 35Class 42Class 44

Vienna Codes

No Vienna codes available.

Goods and services

Class 9

Downloadable electronic educational and professional publications, namely, newsletters, fact sheets, and brochures featuring information on research, testing, diagnosis, and treatment for lung cancer

Class 35

Business management, business administration, and office function services in the nature of the facilitation and management of the collection, tracking, and maintenance of data relating to the testing, diagnosis, and treatment of lung cancer from medical providers, patients, medical researchers, and medical, biopharmaceutical, and biotechnology companies; business administration and office function services in the nature of the coordinating the collection, compilation, tracking, and maintenance of information and data relating to the testing, diagnosis, and treatment of lung cancer; Market intelligence services, namely, providing therapeutic insights and benchmarking information to stakeholders in the fields of medicine and healthcare; Promoting collaboration within the medical, research, scientific, and pharmaceutical, biopharmaceutical and biotechnology communities to achieve advances in lung cancer testing, diagnosis, and treatment; Promoting the exchange of information within the medical, research, scientific, and pharmaceutical, biopharmaceutical and biotechnology communities to achieve advances in lung cancer testing, diagnosis, and treatment; Providing information for the development of best practices for the testing, diagnosis, and treatment of lung cancer

Class 42

Research services, namely, organizing collaborative research and development of protocols regarding the testing, diagnosis, and treatment of lung cancer for medical research purposes; Organizing collaboration in medical research and data collection around the testing, diagnosis, and treatment of lung cancer for medical research purposes; Organizing genomic, medical, biomedical and health care related research regarding lung cancer for medical research purposes; Providing medical research information in the field of lung cancer; Providing medical and scientific research information in the field of lung cancer

Class 44

Healthcare services, namely, collection of data and information on research, testing, diagnosis, and treatment of lung cancer for treatment and diagnostic purposes; Providing medical informational services for the purpose of raising awareness, and disseminating best practices for the testing, diagnosis, and treatment of lung cancer

Publications

History of USPTO decisions and trademark events.

26 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

07/05/2022

R.PR

REGISTERED-PRINCIPAL REGISTER

07/05/2022

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

04/19/2022

PUBO

PUBLISHED FOR OPPOSITION

04/19/2022

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

03/30/2022

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

03/12/2022

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

01/29/2022

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

01/28/2022

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

01/28/2022

AAUA

NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED

10/06/2021

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

10/05/2021

GNRT

NON-FINAL ACTION E-MAILED

10/05/2021

CNRT

NON-FINAL ACTION WRITTEN

10/05/2021

IUAA

USE AMENDMENT ACCEPTED

10/05/2021

AUPC

AMENDMENT TO USE PROCESSING COMPLETE

08/16/2021

IUAF

USE AMENDMENT FILED

08/16/2021

EAAU

TEAS AMENDMENT OF USE RECEIVED

08/15/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

08/12/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

08/12/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

08/12/2021

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

05/19/2021

GNRT

NON-FINAL ACTION E-MAILED

05/19/2021

CNRT

NON-FINAL ACTION WRITTEN

05/19/2021

DOCK

ASSIGNED TO EXAMINER

05/14/2021

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

05/07/2021

NWAP

NEW APPLICATION ENTERED

02/06/2021

Continuous trademark protection

Get notified about every new filing that threatens MYLUNG CONSORTIUM or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.